For
UK
audiences
The professional's guide to product selection
The professional's guide to product selection
Long acting muscarinic antagonist, long-acting beta 2 agonist and inhaled corticosteroid.
Two inhalations twice daily
For the maintenance treatment of moderate to severe COPD.
Use only if potential benefit outweighs risk in the case of hepatic failure, pregnancy and when breast feeding.
Pressurised inhalation
Pressurised inhalation
Trixeo Aerosphere 5 mcg/7.2 mcg/160 mcg, 120 doses
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with long-acting muscarinic antagonist.
Adult: one inhalation twice daily.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Short-acting selective beta2 agonist.
For acute bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms.
For prophylaxis of allergen- or exercise-induced bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: 200 micrograms.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Long-acting muscarinic antagonist, Long-acting beta 2 agonist.
Adult: two inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Combisal 25/125
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Combisal 25/50
• Over 4 years for prophylaxis of asthma: two inhalations twice daily, but can be reduced to two inhalations once daily.
Combisal 25/250
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Long-acting selective beta2 agonist with long-acting muscarinic antagonist.
Adult: one inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/3 pressurised inhaler
Asthma, maintenance therapy
• Child 12–17 years: Initially 2–4 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
• Adult: Initially 2–4 inhalations twice daily, increased if necessary up to 8 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
Asthma, maintenance and reliever therapy
• Over 12 years: Maintenance 4 inhalations daily in 1–2 divided doses, increased if necessary up to 4 inhalations twice daily; 2 inhalations as required for relief of symptoms, increased if necessary up to 12 inhalations as required, usual max. 16 inhalations per day; up to 24 inhalations daily can be used for a limited time under medical supervision.
Symbicort 200/6 Pressurised inhaler
COPD
• Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/6 Turbohaler
• 6–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to 1 daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses; 1 inhalation for relief of symptoms and increase to 6 if required. A maximum of 8 inhalations per day, but 12 can be given under medical supervision.
Symbicort 200/6 Turbohaler
• 12–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to one daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses but can be increased to 2 inhalations twice daily if needed; 1 inhalation for relief of symptoms and increase to 6 inhalations if required. A maximum of 8 inhalations per day, but 12 can be given for a limited time under medical supervision.
• Adult for COPD: 1 inhalation twice daily.
Symbicort 400/12 Turbohaler
• 12–17 years for asthma maintenance: 1 inhalation twice daily, but can be reduced to 1 inhalation daily.
• Adult for asthma maintenance: 1 inhalation twice daily, increased to 2 inhalations twice daily if required and decreased to 1 inhalation daily if controlled.
• Adult for COPD: 1 inhalation twice daily.
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.
By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.
COPD
By inhalation of powder
• Adult: 12 mcg twice daily
By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.
Long-acting muscarinic antagonist, Long-acting beta 2 agonist.
Adult: two inhalations twice daily.
Long-acting selective beta2 agonist.
Oxis
By inhalation of powder for chronic asthma
• 6–17 years: 6–12 micrograms 1–2 times a day (max. per dose 12 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 48 micrograms per day.
• Adult: 6–12 micrograms 1–2 times a day, increased if necessary up to 24 micrograms twice daily (max. per dose 36 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 72 micrograms per day.
By inhalation of powder for relief of bronchospasm
• Over 6 years: 6–12 mcg up to twice daily
By inhalation of powder for prophylaxis of exercise-induced asthma
• Over 6 years: 6–12 mcg before exercise
• Adult: 12 mcg before exercise
By inhalation powder for COPD
• Adult: 12 micrograms 1–2 times a day (max. per dose 24 micrograms), for symptom relief additional doses up to maximum daily dose can be taken; maximum 48 micrograms per day.
Long-acting selective beta2 agonist
Reversible airways obstruction in patients requiring long-term regular broncodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma only in patients who regularly use inhaled corticosteroid (not for immediate relief of acute asthma)
• Child 5–11 years: 50 mcg, twice daily.
• Over 12 years: by inhalation, 50 mcg twice daily. Up to 100 mcg twice daily for more severe airway obstruction.
For COPD
• Adult: 50 mcg, twice daily.
Long-acting selective beta2 agonist.
• Over 18 years by inhalation: 5 mcg (2 puffs), once daily.
Long-acting muscarinic receptor antagonist, long-acting selective beta2 agonist with corticosteroid.
Trimbow 87/5/9 for moderate to severe COPD or asthma maintenance therapy
Adult: 2 inhalations twice daily.
Trimbow 172/5/9 for asthma maintenance therapy
Adult: 2 inhalations twice daily.
Trimbow NEXThaler 88/5/9 for moderate to severe COPD
Adult: 2 inhalations twice daily.